CAPE TOWN, South Africa & GENEVA, Switzerland — In a transformative milestone for global HIV prevention published in The New England Journal of Medicine (NEJM), data from the pivotal Phase 3 PURPOSE 1 and PURPOSE 2 clinical trials confirm that lenacapavir—the first-in-class, long-acting capsid inhibitor administered as a subcutaneous injection once every six months—delivers unprecedented protection against HIV acquisition. Across more than 5,300 adolescent girls and young cisgender women in sub-Saharan Africa, twice-yearly lenacapavir achieved zero HIV infections, establishing 100% efficacy relative to background incidence.
Concurrently, the multinational PURPOSE 2 trial across Latin America, Africa, Southeast Asia, and the United States demonstrated a 96% relative risk reduction in HIV acquisition among gay and bisexual cisgender men, transgender women, transgender men, and non-binary individuals. In response to these clinical findings, manufacturer Gilead Sciences executed royalty-free voluntary licensing agreements with six generic pharmaceutical manufacturers, establishing a procurement pathway to supply low-cost versions to 120 high-incidence, lower-income countries.
Epidemiological Context & The Capsid Inhibition Mechanism
Globally, approximately 1.3 million new HIV acquisitions occur annually, with adolescent girls and young women in sub-Saharan Africa accounting for nearly 60% of all new infections in the region. Although daily oral pre-exposure prophylaxis (PrEP)—such as tenofovir disoproxil fumarate/emtricitabine (F/TDF, Truvada) and tenofovir alafenamide/emtricitabine (F/TAF, Descovy)—demonstrates high biological efficacy when taken consistently, real-world effectiveness has been severely blunted by adherence barriers. Stigma, daily pill fatigue, fear of disclosure, structural marginalization, and partner violence frequently compromise daily regimen persistence among key populations.
Lenacapavir introduces a distinct pharmacological mechanism that circumvents the daily oral compliance bottleneck:
Unlike traditional reverse transcriptase or integrase inhibitors, lenacapavir selectively binds to the interface between adjacent capsid protein (CA) subunits. This multi-stage inhibition prevents nuclear import of the viral pre-integration complex, destabilizes capsid uncoating, and disrupts proper capsid assembly during the late stages of viral maturation, providing durable, multi-checkpoint antiviral suppression.
Phase 3 Trial Architecture & Efficacy Findings
The clinical evidence supporting lenacapavir was established across two rigorous, active-controlled Phase 3 trials designed to evaluate both superiority over background HIV incidence (bHIV) and non-inferiority/superiority against daily oral F/TDF.
Primary Endpoints and Safety Analysis
- PURPOSE 1 Results: In the primary interim analysis, zero HIV acquisitions occurred among 2,134 women receiving lenacapavir across 3,386 person-years of follow-up. In contrast, 39 incident cases occurred in the F/TAF group (incidence 2.02 per 100 person-years) and 16 in the F/TDF group (incidence 1.69 per 100 person-years). Plasma drug concentration monitoring revealed that low adherence accounted for the lack of efficacy in the oral PrEP arms, directly contrasting with the complete protection of the injectable depot.
- PURPOSE 2 Results: Among 2,180 participants across 88 sites in Argentina, Brazil, Mexico, Peru, South Africa, Thailand, and the US, lenacapavir reduced HIV incidence to 0.10 per 100 person-years. This represented a 96% reduction compared to the background incidence (IRR 0.04; 95% CI, 0.01 to 0.18; p < 0.001) and demonstrated 89% greater efficacy than daily oral F/TDF (IRR 0.11; 95% CI, 0.02 to 0.51; p = 0.002).
- Safety and Tolerability: Injection-site reactions (ISRs)—predominantly mild-to-moderate erythema, pain, or transient subcutaneous nodules—occurred in 68% of lenacapavir recipients but led to treatment discontinuation in less than 1% of participants. No systemic toxicities or drug-related deaths were observed.
Expert Commentary from Investigators and Global Leaders
Principal investigators and international health leadership underscored that eliminating implementation gaps is critical to translating clinical trial success into epidemic control.
"If lenacapavir is approved and delivered rapidly, safely, and affordably to those who need or want it, this breakthrough could profoundly accelerate progress toward ending HIV transmission. Twice-yearly dosing directly removes the adherence hurdles that have kept daily oral PrEP from realizing its full potential among young African women." — Professor Linda-Gail Bekker, Lead Investigator for PURPOSE 1 and Director of the Desmond Tutu HIV Centre, University of Cape Town
"To stem the tide of new infections and protect young women and marginalised populations, long-acting medicines are vital. Lenacapavir could be game-changing—if all who would benefit can access it. Gilead must match global ambition by expanding voluntary licenses to cover all low- and middle-income countries where key populations live, ensuring affordable pricing from day one." — Winnie Byanyima, Executive Director of UNAIDS and Under-Secretary-General of the United Nations
"Securing an affordable target price of approximately $40 per year for generic twice-yearly lenacapavir proves that cutting-edge biomedical innovations can be made accessible in high-burden settings without decade-long procurement delays." — Dr. Philippe Duneton, Executive Director, Unitaid
Access Framework & Generic Licensing Implications
In October 2024, Gilead Sciences finalized royalty-free voluntary licensing agreements with six generic manufacturers:
- Dr. Reddy's Laboratories (India)
- Emcure Pharmaceuticals (India)
- Hetero Labs (India)
- Mylan / Viatris (United States / India)
- Eva Pharma (Egypt)
- Ferozsons Laboratories (Pakistan)
Under these agreements, licensed manufacturers are authorized to produce and supply generic formulations of lenacapavir to 120 resource-limited nations, representing predominantly low- and lower-middle-income countries across sub-Saharan Africa, parts of Southeast Asia, and the Caribbean.
Critical Access Dynamics and Policy Challenges
- Bridging Supply & Bilateral Commitments: To bridge the estimated 24- to 36-month timeline required for generic manufacturing scale-up, bioequivalence testing, and WHO Prequalification, Gilead has committed to supply originator lenacapavir at non-profit pricing to PEPFAR and the Global Fund, prioritizing national registrations across 18 high-burden priority countries (including South Africa, Kenya, Uganda, Nigeria, Mozambique, and Rwanda).
- Middle-Income Exclusion Concerns: Civil society groups and UNAIDS have raised concerns regarding the geographic scope of the licenses. Upper-middle-income countries in Latin America (e.g., Brazil, Colombia, Mexico) and Eastern Europe—which account for approximately 41% of global new HIV infections and participated in clinical validation during PURPOSE 2—are excluded from the generic territory, leaving them subject to commercial pricing negotiations.
- Production Economics: While originator lenacapavir is commercialized at approximately $42,250 per patient/year for multi-drug resistant treatment indications in high-income markets, health economics modeling by the University of Liverpool and the Clinton Health Access Initiative (CHAI) indicates that mass-produced generic lenacapavir for PrEP can be profitably manufactured for $40 to $45 per patient/year (inclusive of two injections and active pharmaceutical ingredient synthesis).
With national regulatory filings underway and World Health Organization clinical guideline updates advancing, the successful scale-up of twice-yearly lenacapavir represents a critical opportunity to alter the trajectory of the global HIV epidemic by 2030.
Sources Cited
- The New England Journal of Medicine:
- The New England Journal of Medicine:
- UNAIDS Official Statement:
- Gilead Sciences Regulatory Disclosures:
- Unitaid & CHAI Market Shaping Announcement:
- World Health Organization (WHO):
FIRAT Editorial Board
Institutional Research Desk · Foresight Institute of Research and Translation
The collective editorial and research translation board of FIRAT, synthesising peer-reviewed evidence, policy briefs, and division milestones across our seven foundational research pillars.
